These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 3079350)

  • 1. Misclassification in epidemiologic studies of adverse drug reactions using large managerial data bases.
    Graham DJ; Smith CR
    Am J Prev Med; 1988; 4(2 Suppl):15-24. PubMed ID: 3079350
    [No Abstract]   [Full Text] [Related]  

  • 2. Critical reflection on the collection and evaluation of adverse drug reaction data.
    Venulet J
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S48-53. PubMed ID: 3842691
    [No Abstract]   [Full Text] [Related]  

  • 3. Adverse drug reactions.
    Turner P
    Hum Toxicol; 1986 May; 5(3):161-2. PubMed ID: 3710492
    [No Abstract]   [Full Text] [Related]  

  • 4. Research methods in drug surveillance.
    Engel RR; Grohmann R; Rüther E; Hippius H
    Pharmacopsychiatry; 2004 Mar; 37 Suppl 1():S12-5. PubMed ID: 15052510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Propensity score methods in drug safety studies: practice, strengths and limitations.
    Wang J; Donnan PT
    Pharmacoepidemiol Drug Saf; 2001; 10(4):341-4. PubMed ID: 11760497
    [No Abstract]   [Full Text] [Related]  

  • 6. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 7. Collection and analysis of drug safety data in pregnancy.
    Moretti M
    Can J Clin Pharmacol; 2007; 14(1):e34-6. PubMed ID: 17213508
    [No Abstract]   [Full Text] [Related]  

  • 8. [Necessity and difficulties of quantitative drug monitoring].
    Lagier G; Dally S; Vincens M; Castot A
    Therapie; 1983; 38(3):319-23. PubMed ID: 6612668
    [No Abstract]   [Full Text] [Related]  

  • 9. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 11. Pharmacovigilance in India: how safe are the new drugs? How sure are we?
    Joshi SR; Sapatnekar SM
    J Assoc Physicians India; 2008 Dec; 56():933-4. PubMed ID: 19322970
    [No Abstract]   [Full Text] [Related]  

  • 12. [Pharmaco-morbidity linking: a potential instrument for post-marketing surveillance].
    Stricker BH; Herings RM; Bakker A; Valkenburg HA; Sturmans F
    Ned Tijdschr Geneeskd; 1990 Sep; 134(39):1886-9. PubMed ID: 2215766
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential role of postmarketing research.
    Venulet J
    Drugs Exp Clin Res; 1987; 13(11):673-83. PubMed ID: 3443043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDA attempting to overcome major roadblocks in monitoring drug safety.
    Zielinski SL
    J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
    [No Abstract]   [Full Text] [Related]  

  • 15. The diagnosis of adverse medical events associated with drug treatment.
    Stephens MD
    Adverse Drug React Acute Poisoning Rev; 1987; 6(1):1-35. PubMed ID: 3303863
    [No Abstract]   [Full Text] [Related]  

  • 16. [Detection of drug side effects at the Heidelberg Medical Clinic].
    Jacubeit T; Drisch D
    Verh Dtsch Ges Inn Med; 1989; 95():690-3. PubMed ID: 2603505
    [No Abstract]   [Full Text] [Related]  

  • 17. [30 years' spontaneous recording systems of German physicians--results and experiences].
    Kimbel KH
    Verh Dtsch Ges Inn Med; 1989; 95():683-6. PubMed ID: 2603503
    [No Abstract]   [Full Text] [Related]  

  • 18. Measuring adverse drug reactions in a postmarketing surveillance system.
    Fisher S; Bryant SG; Kluge RM
    Psychopharmacol Bull; 1986; 22(1):272-7. PubMed ID: 3726073
    [No Abstract]   [Full Text] [Related]  

  • 19. An adverse drug reaction reporting program.
    Wasan SM; Marshall LB
    Can J Hosp Pharm; 1989 Dec; 42(6):239-41. PubMed ID: 10318356
    [No Abstract]   [Full Text] [Related]  

  • 20. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.